The company's gentuximab injection is an anti-vascular endothelial growth factor receptor 2 (VEGFR2) monoclonal antibody that can specifically bind to VEGFR2, block the VEGF-VEGFR2 signaling pathway, inhibit tumor angiogenesis, and thus inhibit tumor cell growth. During the reporting period, the company continued to promote the enrollment of patients in the Phase III clinical trial of gentuximab injection for the indication of advanced gastric or gastroesophageal junction adenocarcinoma.